SOURCE: Cytomedix, Inc.

Cytomedix, Inc.

April 02, 2012 08:30 ET

Cytomedix to Present at the 11th Annual Needham Healthcare Conference

GAITHERSBURG, MD--(Marketwire - Apr 2, 2012) - Cytomedix, Inc. (OTCBB: CMXI) (the "Company"), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced that Edward L. Field, Chief Operating Officer of Cytomedix, will present a corporate overview and update at the 11th Annual Needham Healthcare Conference taking place from April 3-4, 2012 at The New York Palace Hotel, New York City. The Company's presentation will take place on Tuesday, April 3, 2012 at 9:20 a.m. ET.

Company management will be available for one-on-one meetings with investors participating in the conference. For those who would like to schedule an appointment with Cytomedix' management, please contact Anne Marie Fields, LHA, at 212-838-3777 or afields@lhai.com or contact your Needham & Company representative.

The presentation will be webcast live at www.cytomedix.com where it will also be archived for 90 days and at http://wsw.com/webcast/needham51/cmxi.

About Cytomedix, Inc.

Cytomedix, Inc. develops, sells and licenses regenerative biological therapies primarily for wound care, inflammation and angiogenesis. The Company markets the AutoloGel™ System, a device for the production of autologous platelet rich plasma ("PRP") gel for use on a variety of exuding wounds; the Angel® Whole Blood Separation System, a blood processing device and disposable products used for the separation of whole blood into red cells, platelet poor plasma ("PPP") and PRP in surgical settings; and the activAT® Autologous Thrombin Processing Kit, which produces autologous thrombin serum from PPP. The activAT® kit is sold exclusively in Europe and Canada, where it provides a completely autologous, safe alternative to bovine-derived products. On February 8, 2012 Cytomedix closed the acquisition of Aldagen, a biopharmaceutical company developing regenerative cell therapies based on its proprietary ALDH bright cell ("ALDHbr") technology, currently in a Phase 2 trial for the treatment of ischemic stroke. For additional information please visit www.cytomedix.com

Safe Harbor Statement
Statements contained in this press release not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix' actual results may differ materially due to a number of factors, many of which are beyond Cytomedix' ability to predict or control, including among many others, risks and uncertainties related to the Company's ability to successfully integrate the Aldagen acquisition, to successfully manage contemplated clinical trials, to manage and address the capital needs, human resource, management, compliance and other challenges of a larger, more complex and integrated business enterprise, viability and effectiveness of the Company's sales approach and overall marketing strategies, commercial success or acceptance by the medical community, competitive responses, the Company's ability to raise additional capital and to continue as a going concern, and Cytomedix's ability to execute on its strategy to market the AutoloGel™ System as contemplated. To the extent that any statements made here are not historical, these statements are essentially forward-looking. The Company uses words and phrases such as "believes", "forecasted," "projects," "is expected," "remain confident," "will" and/or similar expressions to identify forward-looking statements in this press release. Undue reliance should not be placed on forward-looking information. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. Additional risks that could affect our future operating results are more fully described in our U.S. Securities and Exchange Commission filings, including our Annual Report for the year ended December 31, 2011 and other subsequent filings. These filings are available at www.sec.gov.

Contact Information

  • Contacts:
    Cytomedix, Inc.
    Martin Rosendale
    Chief Executive Officer
    Andrew Maslan
    Chief Financial Officer
    David Jorden
    Executive Chairman
    (240) 499-2680

    Investor Inquiries
    Anne Marie Fields
    LHA
    afields@lhai.com
    (212) 838-3777

    Bruce Voss
    LHA
    bvoss@lhai.com
    (310) 691-7100
    @LHA_IR_PR

    Media Inquiries
    Michelle Linn
    Linnden Communications
    linnmich@comcast.net
    (508) 362-3087